Oncology
Advanced Refractory Solid Tumors
1
Pipeline Programs↗
4
Active Trials↗
7
Companies Involved↗
Advanced Refractory Solid Tumors is an early-stage landscape with 1 program across 7 companies. The most active players are Taivex Therapeutics Corporation, MBrace Therapeutics, Progen Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
24
clinical trials
Completed11 · 46%
Unknown status5 · 21%
Recruiting3 · 13%
Suspended2 · 8%
Withdrawn1 · 4%
Terminated1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
24 trials
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07327411·40 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)